This opinion piece endorses AMGN’s unexpected buyout of DeCode Genetics: http://www.xconomy.com/boston/2012/12/10/the-road-to-predictable-innovation-genomics-in-drug-rd/ I find it a little hard to believe that there is $400M+ of commercial value in a firm that went bankrupt a few years ago, but I could well be wrong.